December 2017 | Vol 6 | Issue 9 (Supplement)
Re-defining the role of EUS in pancreatic adenocarcinoma in 2017
Pancreatic ductal adenocarcinoma (PDAC) is a very severe disease, considered in the recent years to be the fifth malignancy in the Western Countries.
Among those, PDAC is the most aggressive being ...
Pancreatic ductal adenocarcinoma epidemiology and risk assessment: Could we prevent? Possibility for an early diagnosis
It is estimated that pancreatic ductal adenocarcinoma (PDAC) will become the second leading cause of cancer-related deaths by 2030. Currently, only 15%–20...
Pancreatic ductal adenocarcinoma in 2017: Time to change the therapeutic algorithm?
Historically, patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC) were offered surgical resection as the first modality of therapy. However, the v...
The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective
Over the past 15 years, therapeutic strategies have evolved toward a personalized approach, leading to significant clinical benefit in many tumors. Early diagnosis, prog...
The resectable pancreatic ductal adenocarcinoma: To FNA or not to FNA? A diagnostic dilemma, introduction
In most patients (up to 95%), pancreatic ductal adenocarcinoma (PDAC) is diagnosed late with locally advanced or metastatic disease , with a low overall 5-year survival rate <5%.[3...
Abstracting and Indexing Information
The journal is registered with the following abstracting partners:
Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Exlibris – Primo Central, Google Scholar, Hinari, Infotrieve, National Science Library, ProQuest, TdNet
The journal is indexed with, or included in, the following:
EMBASE/ Excerpta Medica, Index Copernicus, PubMed Central, Scimago Journal Ranking, SCOPUS, Science Citation Index Expanded, Web of Science
as reported in the 2016 Journal Citation Reports®
(Thomson Reuters, 2017): 2.728